Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-10-10
DOI
10.1038/s41598-017-13746-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury
- (2017) Abdelrahman Y. Fouda et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis
- (2016) Bryna S. M. Chow et al. DIABETOLOGIA
- Compound 21, a selective agonist of angiotensin AT2receptors, prevents endothelial inflammation and leukocyte adhesionin vitroandin vivo
- (2015) Amanda K Sampson et al. BRITISH JOURNAL OF PHARMACOLOGY
- Angiotensin II in inflammation, immunity and rheumatoid arthritis
- (2015) Y. Chang et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A Nonpeptide Angiotensin II Type 2 Receptor Agonist Prevents Renal Inflammation in Early Diabetes
- (2015) Luis C. Matavelli et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Expressions of local renin-angiotensin system components in chondrocytes
- (2014) I. Tsukamoto et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Angiotensin AT2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production
- (2014) Isha Dhande et al. HYPERTENSION RESEARCH
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Angiotensin II type 2 receptor correlates with therapeutic effects of losartan in rats with adjuvant-induced arthritis
- (2013) Di Wang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats
- (2011) Asia Rehman et al. HYPERTENSION
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity
- (2010) D. H. Solomon et al. ANNALS OF THE RHEUMATIC DISEASES
- High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis
- (2010) Christophe Meune et al. Archives of Cardiovascular Diseases
- Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells
- (2010) Chunjie Han et al. ATHEROSCLEROSIS
- Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor κB
- (2010) Franziska Rompe et al. HYPERTENSION
- Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis
- (2009) Beatrix Bartok et al. IMMUNOLOGICAL REVIEWS
- Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis
- (2008) M E Perry et al. ANNALS OF THE RHEUMATIC DISEASES
- Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis
- (2008) Andreas J. Flammer et al. CIRCULATION
- Role of the renin–angiotensin system in vascular inflammation
- (2008) Chiara Marchesi et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started